Contract pharmaceutical smallcap sponsored by Medipal and crossholders JCR Pharma produces ugly H1 results, but they appear "in-line." Guidance is unchanged. And they announce a buyback people can see
What is covered in the Full Insight:
Introduction to JCR Pharma's Results
Earnings Announcement Details
Dividend and Buyback Plans
Shareholder Structure and Market Dynamics
Long-term Prospects and Investment Summary
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.